Critical Reviews in Oncology/Hematology,
Journal Year:
2024,
Volume and Issue:
207, P. 104604 - 104604
Published: Dec. 26, 2024
In
recent
years,
cancer
immunotherapy
has
received
widespread
attention
due
to
significant
tumor
clearance
in
some
malignancies.
Various
approaches,
including
vaccines,
immune
checkpoint
inhibitors,
oncolytic
virotherapy,
bispecific
T
cell
engagers,
and
adoptive
transfer,
have
completed
or
are
undergoing
clinical
trials
for
prostate
cancer.
Despite
blockade's
extraordinary
effectiveness
treating
a
variety
of
cancers,
targeted
treatment
using
the
system
is
still
its
infancy.
Multiple
factors
heterogeneity
cancer,
cold
microenvironment,
low
level
neoantigens,
contribute
poor
response.
Significant
effort
being
devoted
improving
immune-based
therapy.
Recently,
several
key
discoveries
demonstrate
that
agents
may
be
used
promise
better
prognosis
patients
as
part
combination
strategies
with
other
targeting
tumor-associated
mechanism
resistance.
Here,
this
review
comprehensively
examines
advancements
exploring
potential
synergistic
effects
when
combined
modalities
enhance
efficacy.
Frontiers in Endocrinology,
Journal Year:
2024,
Volume and Issue:
15
Published: June 3, 2024
Prostate
cancer
(PCa)
is
commonly
occurred
with
high
incidence
in
men
worldwide,
and
many
patients
will
be
eventually
suffered
from
the
dilemma
of
castration-resistance
time
disease
progression.
Castration-resistant
PCa
(CRPC)
an
advanced
subtype
heterogeneous
carcinogenesis,
resulting
poor
prognosis
difficulties
therapy.
Currently,
disorders
androgen
receptor
(AR)-related
signaling
are
widely
acknowledged
as
leading
cause
CRPC
development,
some
non-AR-based
strategies
also
proposed
for
clinical
analyses.
The
initiation
a
consequence
abnormal
interaction
regulation
among
molecules
pathways
at
multi-biological
levels.
In
this
study,
CRPC-associated
genes,
RNAs,
proteins,
metabolites
were
manually
collected
integrated
by
comprehensive
literature
review,
they
functionally
classified
compared
based
on
role
during
evolution,
i.e.,
drivers,
suppressors,
biomarkers,
etc.
Finally,
translational
perspectives
data-driven
artificial
intelligence-powered
systems
biology
analysis
discussed
to
highlight
significance
novel
molecule-based
approaches
precision
medicine
holistic
healthcare.
Cell Regeneration,
Journal Year:
2024,
Volume and Issue:
13(1)
Published: Oct. 29, 2024
Abstract
Prostate
cancer
is
a
malignant
tumor
of
the
male
urological
system
with
highest
incidence
rate
in
world,
which
seriously
threatens
life
and
health
middle-aged
elderly
men.
The
progression
prostate
involves
interaction
between
cells
microenvironment.
Understanding
mechanisms
pathogenesis
disease
important
to
guide
diagnosis
therapy.
emergence
single-cell
RNA
sequencing
(scRNA-seq)
spatial
transcriptome
(ST-seq)
technologies
has
brought
breakthroughs
study
cancer.
It
makes
up
for
defects
traditional
techniques
such
as
fluorescence-activated
cell
sorting
that
are
difficult
elucidate
cell-specific
gene
expression.
This
review
summarized
heterogeneity
functional
changes
microenvironment
revealed
by
scRNA-seq
ST-seq,
aims
provide
reference
optimal
treatment
bioRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 8, 2024
Abstract
Immune
checkpoint
therapy
for
prostate
cancer
(PCa)
has
failed
in
clinical
trials;
however,
the
precise
underlying
mechanisms
involved
remain
elusive.
PCa,
a
classic
"immune-cold”
tumor,
is
characterized
by
an
immunosuppressive
tumor
microenvironment.
Within
this
milieu,
macrophages,
predominant
immune
cell
population,
have
propensity
to
infiltrate
hypoxic
zones
of
tumors.
In
previous
study,
we
showed
that
Yin
Yang
1
(YY1)
highly
expressed
macrophages
PCa
tissues.
Here,
through
multiplexed
imaging
mass
cytometry
(IMC)
tissue
microarray,
further
demonstrate
YY1
+
aggregate
areas
tumors
and
hypoxia
promotes
phase
separation
nucleus
increasing
tyrosine
phosphorylation
macrophages.
Furthermore,
binds
NUSAP1
SUMOylation
HIF-1α,
which
stabilization
HIF-1α
protein.
We
also
demonstrated
either
treatment
with
small
molecule
inhibitor
(tenapanor)
decrease
YY1–NUSAP1–HIF-1α
interaction
or
myeloid-specific
gene
knockout
impairs
subcutaneous
formation.
present
first-generation
tetrahedral
DNA
nanostructure
(TDN)
based
on
proteolysis
targeting
chimera
(PROTAC)
technique,
named
YY1-DcTAC,
targets
degrades
tumor-associated
mouse
model,
YY1-DcTAC
exhibited
prolonged
drug
efficacy,
robust
macrophage-specific
responsiveness,
potent
antitumor
effects,
increased
CD8
T
infiltration.
summary,
our
findings
underscore
pivotal
role
within
hypoxia/HIF-1α
pathway
affirm
therapeutic
potential
treating
PCa.
Critical Reviews in Oncology/Hematology,
Journal Year:
2024,
Volume and Issue:
207, P. 104604 - 104604
Published: Dec. 26, 2024
In
recent
years,
cancer
immunotherapy
has
received
widespread
attention
due
to
significant
tumor
clearance
in
some
malignancies.
Various
approaches,
including
vaccines,
immune
checkpoint
inhibitors,
oncolytic
virotherapy,
bispecific
T
cell
engagers,
and
adoptive
transfer,
have
completed
or
are
undergoing
clinical
trials
for
prostate
cancer.
Despite
blockade's
extraordinary
effectiveness
treating
a
variety
of
cancers,
targeted
treatment
using
the
system
is
still
its
infancy.
Multiple
factors
heterogeneity
cancer,
cold
microenvironment,
low
level
neoantigens,
contribute
poor
response.
Significant
effort
being
devoted
improving
immune-based
therapy.
Recently,
several
key
discoveries
demonstrate
that
agents
may
be
used
promise
better
prognosis
patients
as
part
combination
strategies
with
other
targeting
tumor-associated
mechanism
resistance.
Here,
this
review
comprehensively
examines
advancements
exploring
potential
synergistic
effects
when
combined
modalities
enhance
efficacy.
